AxCellerate is a Swiss BioTech company offering pre-clinical research services through its organ-on-chip technologies, using proprietary systems and human-derived cells to to mimic the complexity of the central and peripheral nervous system.
Products, services, technology
AxCellerate’s core technology, NEUROCHIP, is a human brain-on-chip platform designed to improve preclinical testing of neurological therapies by enabling predictive toxicity, safety, and efficacy assessment in human-derived 3D brain organoids.
Cooperation possibilities
AxCellerate will provide B2B pre-clinical services to assess toxicity, safety and, if a disease model is available, efficacy of new chemical entities before they enter the clinical phase in humans.
- http://www.axcellerate.ch
- Send an email
- Alessandro Giacometti
Some insights
By potentially reducing the animal tests in preclinical and accelerating the transition of new molecules into Phase 1 to 3 in humans.
Because of the technologies we develop and will develop.
Diversified background and experience in venture building, commercial, life sciences, engineering.
By allowing us to expand our network with biopharmaceuticals, CROs, research institutions globally.
Senior executives working in pre-clinical stages with focus in neuroscience and investors.
